Traders should monitor upcoming IND filings and Phase 1 initiations for PRT12396 and PRT13722 as near-term catalysts. The improved cash runway reduces near-term dilution risk, but the company remains pre-revenue with no product sales, so future value hinges on clinical execution.
Price Chart
Executive Summary
Prelude Therapeutics reported its full-year 2025 financial results, showing improved losses and reduced expenses, while providing key R&D updates including FDA clearance of the IND for its JAK2V617F inhibitor PRT12396 and progress on its KAT6A degrader program. The company maintains a cash runway into Q2 2027 with $106.4 million in liquidity.
Key Financial Metrics
Key Facts
- FDA cleared the IND for PRT12396 (JAK2V617F inhibitor), with Phase 1 initiation expected in Q2 2026 in patients with polycythemia vera and myelofibrosis.
- IND filing for PRT13722 (KAT6A degrader) expected mid-2026, with Phase 1 initiation in second half of 2026.
- Cash, cash equivalents, and marketable securities totaled $106.4 million as of December 31, 2025, funding operations into Q2 2027.
- 2025 net loss was $99.5 million ($1.29/share), improved from $127.2 million ($1.68/share) in 2024.
- Revenue increased to $12.14 million in 2025 from $7.0 million in 2024, primarily from collaboration and license agreements.
Financial Impact
Revenue increased 73% YoY to $12.14M; net loss narrowed by $27.7M. R&D and G&A expenses declined significantly due to reduced stock-based compensation and discontinued trials.
Risk Factors
- High dependence on clinical development success of early-stage assets with no guaranteed outcomes.
- Potential for future dilution if additional capital is needed beyond 2027.
- Forward-looking statements are subject to significant risks, including regulatory delays, trial enrollment issues, and manufacturing challenges.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252633 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $4.85 $4.31 | ▼ −11.13% | ▼ −10.41% | $3.88 (−20.00%) |
Sep 10, 2026 6w ago | 8-K | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.88 (−16.92%) |
Sep 10, 2026 6w ago | Press Release | $4.67 $4.59 | ▼ −1.71% | ▼ −2.57% | $3.88 (−16.92%) |
Aug 11, 2026 11w ago | 8-K | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.88 (−27.07%) |
Aug 11, 2026 11w ago | Press Release | $5.32 $5.73 | ▲ +7.71% | ▲ +7.46% | $3.88 (−27.07%) |
May 12, 2026 24w ago | 8-K | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.88 (−16.38%) |
May 12, 2026 24w ago | Press Release | $4.64 $4.66 | ▲ +0.43% | ▼ −0.14% | $3.88 (−16.38%) |
Apr 28, 2026 26w ago | 3 | $4.27 $4.27 | · 0.00% | ▼ −1.02% | $3.88 (−9.13%) |
Apr 21, 2026 27w ago | Insider Cluster | $4.27 $5.23 | ▲ +22.48% | ▲ +21.46% | $3.88 (−9.13%) |
Apr 20, 2026 27w ago | 8-K | $4.51 $4.62 | ▲ +2.44% | ▲ +3.09% | $3.88 (−13.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers